文献速递核素与放射性配体治疗放射性药物与辐射防护

在大鼠模型中联合给予对氨基马尿酸可降低多种放射性药物的肾脏摄取

Reduced Renal Uptake of Various Radiopharmaceuticals with Sodium Paraaminohippurate Coadministration in a Rat Model.
PubMed 文献 · J Nucl Med · 2025-05-01

该临床前研究在Wistar大鼠中比较了对氨基马尿酸与氯化钠或精氨酸-赖氨酸共注射对多种放射性药物肾脏摄取的影响。结果显示,对氨基马尿酸可显著降低多种小分子放射性药物在肾皮质的摄取,而对较大分子无影响,且耐受良好无毒性。

要点

  • 对氨基马尿酸共注射可显著降低多种小肽类放射性药物在肾皮质的摄取。
  • [177Lu]Lu-DOTATOC、[177Lu]Lu-DOTATATE和[177Lu]Lu-DOTA-JR11的肾脏摄取分别降低46%、83%和63%。
  • 对氨基马尿酸耐受良好,未观察到毒性。

核心结论

  • 高浓度对氨基马尿酸共注射可显著降低部分小分子放射性药物的肾脏摄取,提示肾小管分泌及可被高浓度对氨基马尿酸饱和的阴离子转运体发挥作用。
  • 对氨基马尿酸联合用药可能作为靶向放射性药物治疗中快速、安全、便捷的肾保护替代方案。

研究设计与样本

  • 临床前研究,在Wistar大鼠中进行离体生物分布、SPECT/CT和PET分析,比较对氨基马尿酸溶液与氯化钠或精氨酸-赖氨酸溶液共注射对多种放射性药物肾脏摄取的影响。

主要发现

  • 对氨基马尿酸耐受良好,未观察到毒性。
  • 与氯化钠共注射相比,对氨基马尿酸共注射后1小时,小肽类放射性药物[177Lu]Lu-DOTATOC、[177Lu]Lu-DOTATATE、[177Lu]Lu-DOTA-JR11、[177Lu]Lu-DOTA-sargastrin和[177Lu]Lu-DOTARGD在肾皮质的累积活性显著降低。
  • [177Lu]Lu-DOTATOC、[177Lu]Lu-DOTATATE和[177Lu]Lu-DOTA-JR11的肾脏摄取分别降低46%、83%和63%。
  • 肾脏曲线下面积值根据所用化合物不同最多降低60%。
  • 对前列腺特异性膜抗原(PSMA)靶向分子[177Lu]Lu-PSMA-I&T和[68Ga]Ga-PSMA-11观察到程度较轻的对氨基马尿酸介导的肾保护作用;较大重组蛋白[177Lu]Lu-DOTA-Affiline-22(18 kDa)和叶酸衍生物[99mTc]Tc-etarfolatide的肾脏摄取未受影响。

临床怎么用

  • 原文结论提出对氨基马尿酸联合用药可能作为靶向放射性药物治疗中快速、安全、便捷的肾保护替代方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The coinfusion of amino acids with targeted radiopharmaceutical therapy aims to reduce renal toxicity. Unfortunately, this requires a prolonged, large-volume infusion and often results in side effects such as nausea, vomiting, and hyperkalemia. Sodium paraaminohippurate is a nontoxic compound that has historically been used to measure renal plasma flow. It is excreted by the kidneys via glomerular filtration and tubular secretion using organic anion transporters. Paraaminohippurate has a favorable safety profile at plasma concentrations that saturate the maximum transport capacity of tubular cells. Therefore, paraaminohippurate may potentially reduce the renal accumulation of small-molecule radiopharmaceuticals. Methods: Preclinical studies, including ex vivo biodistribution, SPECT/CT, and PET analyses, were performed in Wistar rats to evaluate how coinjection of a paraaminohippurate solution affects the renal uptake of various radiopharmaceuticals compared with coinjection of a NaCl or arginine-lysine solution. Results: Paraaminohippurate was well tolerated, with no toxicity observed. Accumulated activity measured in the renal cortex was significantly lower for the small-peptide radiopharmaceuticals (0.9-2.5 kDa)-[177Lu]Lu-DOTATOC, [177Lu]Lu-DOTATATE, [177Lu]Lu-DOTA-JR11, [177Lu]Lu-DOTA-sargastrin, and [177Lu]Lu-DOTARGD-when paraaminohippurate was coinjected instead of NaCl. The renal uptake of [177Lu]Lu-DOTATOC, [177Lu]Lu-DOTATATE, and [177Lu]Lu-DOTA-JR11 was reduced by 46%, 83%, and 63%, respectively, at 1 h after injection with paraaminohippurate coinjection from the uptake after injection with NaCl. Kidney area-under-the-curve values were reduced by up to 60%, depending on the compound used. To a lesser extent, paraaminohippurate-mediated nephroprotection was observed with the prostate-specific membrane antigen (PSMA)-targeting molecules [177Lu]Lu-PSMA-I&T and [68Ga]Ga-PSMA-11. The renal uptake of the larger recombinant protein [177Lu]Lu-DOTA-Affiline-22 (18 kDa) and the folate derivative [99mTc]Tc-etarfolatide was not affected. These in vivo imaging data were confirmed by ex vivo biodistribution studies. Conclusion: Coinjection of paraaminohippurate at a high concentration was found to significantly reduce the renal uptake of a select number of small-molecule radiopharmaceuticals. This indicates the importance of tubular secretion, as well as the potential role of anion transporters that may be saturated by a high paraaminohippurate plasma concentration. Therefore, paraaminohippurate comedication could serve as a fast, safe, and convenient alternative to amino acid infusion as a nephroprotective agent during targeted radiopharmaceutical therapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Meckel M, Ehrenberg S, Schmidt T, et al. Reduced Renal Uptake of Various Radiopharmaceuticals with Sodium Paraaminohippurate Coadministration in a Rat Model. J Nucl Med. 2025. PMID: 40147849. doi:10.2967/jnumed.124.268411

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。